Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Phase of Trial: Phase II/III
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DIVE
- 09 Aug 2016 Status changed from recruiting to completed.
- 06 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.
- 12 Apr 2016 New trial record